Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial
Filed with ASX · · 1 page · English
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- Safety Review Committee Approves Second Cohort
- No Serious Safety Issues Observed in First Cohort
- First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007
- Argenica Receives $1.38m R&D Tax Incentive Cash Refund
- Further Positive Preclinical Results for ARG-007 In HIE
Later from Argenica Therapeutics
- Safety Review Committee Approves Third Cohort Commencement
- Phase 1 Clinical Trial Progress Update
- SRC Approves Commencement Of Fourth And Final Cohort Dosing
- Successful Completion of Phase 1 Clinical Trial Dosing
- Argenica Awarded $1.2m CRC-P Grant for TBI Project
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics